DR. ANTHONY W. TOLCHER
Osteopathic Medicine at Medical Dr, San Antonio, TX
License number
Texas K6367
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
4383 Medical Dr, San Antonio, TX 78229
Phone
(210) 593-5700
(210) 593-5992 (Fax)
(210) 593-5992 (Fax)
Organization information
See more information about ANTHONY W. TOLCHER at bizstanding.comStart Center - Alexander R Miller MD
4383 Medical Dr, San Antonio, TX 78229
Doing business as:
Start Center - Allan J White MD<br>Start Center - Anthony W Tolcher MD
Site:
Phone:
(210) 593-5700 (Phone)
Categories:
General Surgeons, Oncology Physicians & Surgeons, Physicians & Surgeons, ...
Professional information
Director Of Clinical Research And Co-Founder At Start
Position:
Director of Clinical Research and Co-Founder at START- South Texas Accelerated Research Therapeutics
Location:
San Antonio, Texas Area
Industry:
Research
Work:
START- South Texas Accelerated Research Therapeutics
since Apr 2007
-
Director of Clinical Research and Co-Founder
Institute for Drug Development
1998 - Mar 2007
-
Director of Clinical Research
National Cancer Institute
1992 - 1994
-
Fellow
Education:
National Cancer Institute, NIH 1992 - 1994
The University of British Columbia / UBC 1990 - 1992
Specialty in Oncology, Medical Oncology Residency Program University of Toronto 1987 - 1990
FRCPC, Internal Medicine Residency Program The University of British Columbia / UBC 1982 - 1986
Doctor of Medicine (MD), Medicine
The University of British Columbia / UBC 1990 - 1992
Specialty in Oncology, Medical Oncology Residency Program University of Toronto 1987 - 1990
FRCPC, Internal Medicine Residency Program The University of British Columbia / UBC 1982 - 1986
Doctor of Medicine (MD), Medicine
Skills:
Clinical Trials, Oncology, Cancer, Clinical Research, Translational Medicine, CTMS, Translational Research, GCP, Biotechnology, Drug Development, Biomarkers, CRO, Hematology, Medicine, Lifesciences, Pharmacovigilance, Infectious Diseases, Cancer Research, Healthcare, Medical Writing, Immunology, Therapeutic Areas, ICH-GCP, Oncology Clinical Research, Vaccines, Clinical Monitoring, Internal Medicine, Genetics, Medical Affairs, Pharmaceutical Industry, Protocol, EDC, Pharmacology
Dr. Anthony W Tolcher, San Antonio TX - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
South Texas Oncology Hematology
4383 Medical Dr, San Antonio 78229
(210) 593-5700 (Phone)
4383 Medical Dr, San Antonio 78229
(210) 593-5700 (Phone)
Certifications:
Internal Medicine, 1990, Medical Oncology, 2004
Awards:
Healthgrades Honor Roll
Languages:
English, Spanish
Hospitals:
South Texas Oncology Hematology
4383 Medical Dr, San Antonio 78229
CHRISTUS Santa Rosa Hospital - City Center
333 North Santa Rosa St, San Antonio 78207
Methodist Hospital
7700 Floyd Curl Dr, San Antonio 78229
Northeast Baptist Hospital
8811 Village Dr, San Antonio 78217
4383 Medical Dr, San Antonio 78229
CHRISTUS Santa Rosa Hospital - City Center
333 North Santa Rosa St, San Antonio 78207
Methodist Hospital
7700 Floyd Curl Dr, San Antonio 78229
Northeast Baptist Hospital
8811 Village Dr, San Antonio 78217
Education:
Medical School
University Of British Columbia Faculty Of Medicine
Graduated: 1986
St Pauls Hospital
Graduated: 1987
Toronto Western Hospital University Toro
Graduated: 1990
Wellesley Hospital University Toronto
Graduated: 1988
Bc Canc Agency University Bc
Nci
Graduated: 1994
University Of British Columbia Faculty Of Medicine
Graduated: 1986
St Pauls Hospital
Graduated: 1987
Toronto Western Hospital University Toro
Graduated: 1990
Wellesley Hospital University Toronto
Graduated: 1988
Bc Canc Agency University Bc
Nci
Graduated: 1994
Combination Therapy To Prevent And Treat Diarrhea Induced By Cancer Treatment
US Patent:
2005024, Nov 3, 2005
Filed:
Apr 28, 2005
Appl. No.:
11/119211
Inventors:
Diane Healey - Madison CT, US
Jean Beebe - Salem CT, US
James O'Leary - Mystic CT, US
W. Roberts - Noank CT, US
Anthony Tolcher - San Antonio TX, US
Mark Huberman - Newton MA, US
Jean Beebe - Salem CT, US
James O'Leary - Mystic CT, US
W. Roberts - Noank CT, US
Anthony Tolcher - San Antonio TX, US
Mark Huberman - Newton MA, US
International Classification:
A61K031/425, A61K038/08, A61K031/56, A61K031/138
US Classification:
514016000, 514171000, 514372000, 514651000
Abstract:
This invention relates to a method of treating drug side effects in cancer treatment. More particularly, the present invention relates to preventing, reducing, alleviating, or reversing diarrhea caused by the administration of the isothiazole 3-(4-Bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide in the treatment of cancer comprising the step of administering to a patient in need of such treatment, prior to, simultaneously, or sequentially, a therapeutically effective amount of 3-(4-Bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an anti-diarrheal agent, a bulking agent, or an anti-estrogen. The combinations of the present invention may optionally include an anti-hypertensive agent.
Methods And Compositions For Treating Tumor Diseases
US Patent:
2010016, Jul 1, 2010
Filed:
Feb 29, 2008
Appl. No.:
12/529538
Inventors:
Pedro J. Beltran - Sherman Oaks CA, US
Frank J. Calzone - Westlake Village CA, US
Gregory Friberg - Westlake Village CA, US
Christopher Haqq - Newbury Park CA, US
Anthony W. Tolcher - San Antonio TX, US
Frank J. Calzone - Westlake Village CA, US
Gregory Friberg - Westlake Village CA, US
Christopher Haqq - Newbury Park CA, US
Anthony W. Tolcher - San Antonio TX, US
International Classification:
A61K 39/395, A61K 38/00, A61K 31/7088, A61P 35/04, A61K 39/00, C12Q 1/68, C12Q 1/02
US Classification:
4241331, 4241581, 514 12, 514 44 A, 4241841, 435 6, 435 29
Abstract:
The present invention provides, in part, methods for treating a tumor in a human subject comprising inhibiting IGF-1 receptor signaling, methods of determining whether a tumor is more or less likely to respond to such treatment, and compositions for practicing such methods. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.